Long-Term Treatment of Ovariectomized Mice with Estradiol or Phytoestrogens as a New Model to Study the Role of Estrogenic Substances in the Heart

Planta Medica

Volumn 78, Issue 1, 2012, Pages 6-11

  Nguyen, Ba Tiep ^a   Kararigas, Georgios ^b   Wuttke, Wolfgang ^a   Jarry, Hubertus ^a  

^a and Gemeinnützige Hertie Stiftung   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

cardiac gene expression; equol; estradiol; genistein; long term treatment; phytoestrogens; resveratrol

Indexed keywords

COMPLEMENT COMPONENT C3; EQUOL; ESTRADIOL; GENISTEIN; MESSENGER RNA; PHYTOESTROGEN; RESVERATROL; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE; CARDIOMYOPATHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ESTROGEN THERAPY; FEMALE; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART SIZE; HEART WEIGHT; IGF1 GENE; INFANT; LONG TERM CARE; MORPHOLOGY; MOUSE; NONHUMAN; OVARIECTOMY; UTERUS WEIGHT; ESTROGEN ACTIVITY; HEART FUNCTION; HEART MUSCLE; MENOPAUSAL SYNDROME;

MUS;

EID: 80052771025     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0031-1280228     Document Type: Article

References (45)

1. Isles C. G., Hole D. J., Hawthorne V. M., Lever A. F. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet: 1992; 339 702 706
2. Grodstein F., Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis: 1995; 38 199 210
3. Rees M., Stevenson J. Primary prevention of coronary heart disease in women. Menopause Int: 2008; 14 40 45
4. Rossouw J. E., Anderson G. L., Prentice R. L., LaCroix A. Z., Kooperberg C., Stefanick M. L., Jackson R. D., Beresford S. A., Howard B. V., Johnson K. C., Kotchen J. M., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA: 2002; 288 321 333
5. Arias-Loza P. A., Jazbutyte V., Pelzer T. Genetic and pharmacologic strategies to determine the function of estrogen receptor alpha and estrogen receptor beta in cardiovascular system. Gend Med: 2008; 5 (Suppl. A) S34 S45
6. Kararigas G., Becher E., Mahmoodzadeh S., Knosalla C., Hetzer R., Regitz-Zagrosek V. Sex-specific modification of progesterone receptor expression by 17beta-oestradiol in human cardiac tissues. Biol Sex Differ: 2010; 1 2
7. Ling S., Komesaroff P., Sudhir K. Cellular mechanisms underlying the cardiovascular actions of oestrogens. Clin Sci (Lond): 2006; 111 107 118
8. Grohe C., Kahlert S., Lobbert K., Vetter H. Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol: 1998; 156 R1 R7
9. Nordmeyer J., Eder S., Mahmoodzadeh S., Martus P., Fielitz J., Bass J., Bethke N., Zurbrugg H. R., Pregla R., Hetzer R., Regitz-Zagrosek V. Upregulation of myocardial estrogen receptors in human aortic stenosis. Circulation: 2004; 110 3270 3275
10. Fliegner D., Schubert C., Penkalla A., Witt H., Kararigas G., Dworatzek E., Staub E., Martus P., Ruiz Noppinger P., Kintscher U., Gustafsson J. A., Regitz-Zagrosek V. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol: 2010; 298 R1597 R1606
11. Kararigas G., Fliegner D., Gustafsson J. A., Regitz-Zagrosek V. Role of the estrogen/estrogen-receptor-beta axis in the genomic response to pressure overload-induced hypertrophy. Physiol Genomics: 2011; 43 438 446
12. Regitz-Zagrosek V., Wintermantel T. M., Schubert C. Estrogens and SERMs in coronary heart disease. Curr Opin Pharmacol: 2007; 7 130 139
13. Saltiki K., Alevizaki M. Coronary heart disease in postmenopausal women; the role of endogenous estrogens and their receptors. Hormones (Athens): 2007; 6 9 24
14. Carlson S., Peng N., Prasain J. K., Wyss J. M. Effects of botanical dietary supplements on cardiovascular, cognitive, and metabolic function in males and females. Gend Med: 2008; 5 (Suppl. A) S76 S90
15. Messina M. J., Wood C. E. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J: 2008; 7 17
16. Wuttke W., Jarry H., Seidlova-Wuttke D. Isoflavones-safe food additives or dangerous drugs? Ageing Res Rev: 2007; 6 150 188
17. Mazur W., Adlercreutz H. Overview of naturally occurring endocrine-active substances in the human diet in relation to human health. Nutrition: 2000; 16 654 658
18. Munro I. C., Harwood M., Hlywka J. J., Stephen A. M., Doull J., Flamm W. G., Adlercreutz H. Soy isoflavones: a safety review. Nutr Rev: 2003; 61 1 33
19. Luczak E. D., Leinwand L. A. Sex-based cardiac physiology. Annu Rev Physiol: 2009; 71 1 18
20. Owens J. W., Ashby J. Critical review and evaluation of the uterotrophic bioassay for the identification of possible estrogen agonists and antagonists: in support of the validation of the OECD uterotrophic protocols for the laboratory rodent. Organisation for Economic Co-operation and Development. Crit Rev Toxicol: 2002; 32 445 520
21. Kuiper G. G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology: 1997; 138 863 870
22. Bowers J. L., Tyulmenkov V. V., Jernigan S. C., Klinge C. M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology: 2000; 141 3657 3667
23. Valenzano D. R., Terzibasi E., Genade T., Cattaneo A., Domenici L., Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol: 2006; 16 296 300
24. Mueller S. O., Simon S., Chae K., Metzler M., Korach K. S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci: 2004; 80 14 25
25. Bottner M., Christoffel J., Jarry H., Wuttke W. Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on pituitary function in rats. J Endocrinol: 2006; 189 77 88
26. Rachon D., Seidlova-Wuttke D., Vortherms T., Wuttke W. Effects of dietary equol administration on ovariectomy induced bone loss in Sprague-Dawley rats. Maturitas: 2007; 58 308 315
27. Sehmisch S., Hammer F., Christoffel J., Seidlova-Wuttke D., Tezval M., Wuttke W., Stuermer K. M., Stuermer E. K. Comparison of the phytohormones genistein, resveratrol and 8-prenylnaringenin as agents for preventing osteoporosis. Planta Med: 2008; 74 794 801
28. Seidlova-Wuttke D., Jarry H., Wuttke W. Effects of estradiol benzoate, raloxifen and an ethanolic extract of Cimicifuga racemosa in nonclassical estrogen regulated organs of ovariectomized rats. Planta Med: 2009; 75 1279 1285
29. Stettner M., Kaulfuss S., Burfeind P., Schweyer S., Strauss A., Ringert R. H., Thelen P. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther: 2007; 6 2626 2633
30. Roth C., Schricker M., Lakomek M., Strege A., Heiden I., Luft H., Munzel U., Wuttke W., Jarry H. Autoregulation of the gonadotropin-releasing hormone (GnRH) system during puberty: effects of antagonistic versus agonistic GnRH analogs in a female rat model. J Endocrinol: 2001; 169 361 371
31. Babiker F. A., Lips D. J., Delvaux E., Zandberg P., Janssen B. J., Prinzen F., van Eys G., Grohe C., Doevendans P. A. Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms. Acta Physiol (Oxf): 2007; 189 23 31
32. Arias-Loza P. A., Hu K., Dienesch C., Mehlich A. M., Konig S., Jazbutyte V., Neyses L., Hegele-Hartung C., Heinrich Fritzemeier K., Pelzer T. Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension: 2007; 50 432 438
33. Patten R. D., Pourati I., Aronovitz M. J., Baur J., Celestin F., Chen X., Michael A., Haq S., Nuedling S., Grohe C., Force T., Mendelsohn M. E., Karas R. H. 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res: 2004; 95 692 699
34. Vandenbroucke J. P. The HRT controversy: observational studies and RCTs fall in line. Lancet: 2009; 373 1233 1235
35. Rachon D., Vortherms T., Seidlova-Wuttke D., Wuttke W. Effects of dietary equol on the pituitary of the ovariectomized rats. Horm Metab Res: 2007; 39 256 261
36. Prentice R. L., Langer R. D., Stefanick M. L., Howard B. V., Pettinger M., Anderson G. L., Barad D., Curb J. D., Kotchen J., Kuller L., Limacher M., Wactawski-Wende J. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol: 2006; 163 589 599
37. van Eickels M., Grohe C., Cleutjens J. P., Janssen B. J., Wellens H. J., Doevendans P. A. 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation: 2001; 104 1419 1423
38. Persky A. M., Green P. S., Stubley L., Howell C. O., Zaulyanov L., Brazeau G. A., Simpkins J. W. Protective effect of estrogens against oxidative damage to heart and skeletal muscle in vivo and in vitro. Proc Soc Exp Biol Med: 2000; 223 59 66
39. Munoz-Castaneda J. R., Montilla P., Munoz M. C., Bujalance I., Muntane J., Tunez I. Effect of 17-beta-estradiol administration during adriamycin-induced cardiomyopathy in ovariectomized rat. Eur J Pharmacol: 2005; 523 86 92
40. Pedram A., Razandi M., Aitkenhead M., Levin E. R. Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem: 2005; 280 26339 26348
41. Nelson H. D., Humphrey L. L., Nygren P., Teutsch S. M., Allan J. D. Postmenopausal hormone replacement therapy: scientific review. JAMA: 2002; 288 872 881
42. Chao W., Matsui T., Novikov M. S., Tao J., Li L., Liu H., Ahn Y., Rosenzweig A. Strategic advantages of insulin-like growth factor-I expression for cardioprotection. J Gene Med: 2003; 5 277 286
43. Geraldes P., Sirois M. G., Tanguay J. F. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ Res: 2003; 93 399 405
44. Rachon D., Vortherms T., Seidlova-Wuttke D., Wuttke W. Effects of dietary equol on body weight gain, intra-abdominal fat accumulation, plasma lipids, and glucose tolerance in ovariectomized Sprague-Dawley rats. Menopause: 2007; 14 925 932
45. Miao C. Y., Li Z. Y. The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol advance online publication: 06 04 2011; 10.1111/j.1476-5381.2011.01404.x